PMID- 35905827
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20220930
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 365
DP  - 2022 Oct 15
TI  - Translating results from the cardiovascular outcomes trials with glucagon-like 
      peptide-1 receptor agonists into clinical practice: Recommendations from a 
      Eastern and Southern Europe diabetes expert group.
PG  - 8-18
LID - S0167-5273(22)01085-3 [pii]
LID - 10.1016/j.ijcard.2022.07.017 [doi]
AB  - Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the 
      endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes 
      mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion 
      in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and 
      mortality is common in patients with T2DM, several trials with the use of GLP-1 
      receptor agonists (RAs) have been performed focusing on endpoints related to 
      cardiovascular disease rather than metabolic control of T2DM. Following the 
      positive cardiovascular effects of liraglutide, dulaglutide and semaglutide 
      observed in these trials, major changes in T2DM management guidelines have 
      occurred. This document from a Eastern and Southern European Diabetes Expert 
      Group discusses the results of GLP-1 RA CV outcomes trials, their impact on 
      recent clinical guidelines for the management of T2DM, and some selected 
      combination regimens utilising GLP-1 RAs. We also propose an algorithm for 
      guiding GLP-1 RA-based treatment according to patients' characteristics, which 
      can be easily applied in every day clinical practice.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Janez, Andrej
AU  - Janez A
AD  - Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical 
      Center Ljubljana, Slovenia. Electronic address: andrej.janez@kclj.si.
FAU - Muzurovic, Emir
AU  - Muzurovic E
AD  - Faculty of Medicine, University of Montenegro, Department of Internal Medicine, 
      Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro.
FAU - Stoian, Anca Pantea
AU  - Stoian AP
AD  - Diabetes, Nutrition and Metabolic Diseases Department, Carol Davila University of 
      Medicine and Pharmacy, Bucharest, Romania.
FAU - Haluzik, Martin
AU  - Haluzik M
AD  - Diabetes Centre and Centre for Experimental Medicine, Institute for Clinical and 
      Experimental Medicine and Institute of Endocrinology, Prague, Czech Republic.
FAU - Guja, Cristian
AU  - Guja C
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" 
      University of Medicine and Pharmacy, Bucharest, Romania.
FAU - Czupryniak, Leszek
AU  - Czupryniak L
AD  - Department of Diabetology and Internal Medicine, Medical University of Warsaw, 
      Poland.
FAU - Duvnjak, Lea
AU  - Duvnjak L
AD  - School of Medicine University of Zagreb, Vuk Vrhovac University Clinic, Zagreb, 
      Croatia.
FAU - Lalic, Nebojsa
AU  - Lalic N
AD  - Faculty of Medicine University of Belgrade, Clinic for Endocrinology, Diabetes 
      and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia.
FAU - Tankova, Tsvetalina
AU  - Tankova T
AD  - Department of Endocrinology, Medical University, Sofia, Bulgaria.
FAU - Bogdanski, Pawel
AU  - Bogdanski P
AD  - Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, 
      University of Medical Sciences, Poznan, Poland.
FAU - Papanas, Nikolaos
AU  - Papanas N
AD  - Diabetes Centre, Second Department of Internal Medicine, Democritus University of 
      Thrace, Alexandroupolis, Greece.
FAU - Nunes, Jose Silva
AU  - Nunes JS
AD  - Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar 
      Universitario Lisboa Central, Lisbon, Portugal.
FAU - Kempler, Peter
AU  - Kempler P
AD  - First Department of Medicine, Semmelweis University, Budapest, Hungary.
FAU - Fras, Zlatko
AU  - Fras Z
AD  - Preventive Cardiology Unit, Division of Medicine, University Medical Centre 
      Ljubljana and Chair of Internal Medicine, Medical Faculty, University of 
      Ljubljana, Slovenia.
FAU - Rizzo, Manfredi
AU  - Rizzo M
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and 
      Medical Specialties (Promise), School of Medicine, University of Palermo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220726
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
CIN - Int J Cardiol. 2022 Nov 15;367:63-64. PMID: 36028093
MH  - *Cardiovascular Diseases/drug therapy/epidemiology
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy/epidemiology
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Liraglutide/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Algorithm
OT  - Cardiovascular outcomes trials
OT  - GLP-1 receptor agonists
OT  - Treatment
OT  - Type 2 diabetes mellitus
EDAT- 2022/07/30 06:00
MHDA- 2022/08/30 06:00
CRDT- 2022/07/29 19:14
PHST- 2022/05/29 00:00 [received]
PHST- 2022/07/05 00:00 [revised]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/07/30 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/07/29 19:14 [entrez]
AID - S0167-5273(22)01085-3 [pii]
AID - 10.1016/j.ijcard.2022.07.017 [doi]
PST - ppublish
SO  - Int J Cardiol. 2022 Oct 15;365:8-18. doi: 10.1016/j.ijcard.2022.07.017. Epub 2022 
      Jul 26.